Sung, H. et al. International most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J. Clin. 71, 209–249 (2021).
Xia, C. et al. Most cancers statistics in China and United States, 2022: profiles, traits, and determinants. Chin. Med. J. (Engl) 135, 584–590 (2022).
D’Angelica, M. et al. Patterns of preliminary recurrence in utterly resected gastric adenocarcinoma. Ann. Surg. 240, 808–816 (2004).
Sakuramoto, S. et al. Adjuvant chemotherapy for gastric most cancers with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810–1820 (2007).
Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric most cancers after D2 gastrectomy (CLASSIC): a part 3 open-label, randomised managed trial. Lancet 379, 315–321 (2012).
Kakeji, Y. et al. Three-year outcomes of a randomized part III trial evaluating adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric most cancers: JACCRO GC-07. Gastric Most cancers 25, 188–196 (2022).
Zhang, X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in sufferers with domestically superior gastric or gastro-oesophageal junction adenocarcinoma present process D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, part 3 randomised managed trial. Lancet Oncol 22, 1081–1092 (2021).
Xu, J. et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction most cancers: The ORIENT-16 randomized medical trial. JAMA 330, 2064–2074 (2023).
Liu, T. et al. First-line nivolumab plus chemotherapy vs. chemotherapy in sufferers with superior gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese language subgroup evaluation. Int. J. Most cancers 152, 749–760 (2023).
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for superior gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, part 3 trial. Lancet 398, 27–40 (2021).
Shitara, Okay. et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in domestically superior gastric or gastro-oesophageal most cancers (KEYNOTE-585): an interim evaluation of the multicentre, double-blind, randomised part 3 research. Lancet Oncol. 25, 212 (2023).
Terashima, M., Kang, Y.Okay., Kim, Y.-W., Boku, N., Chung, H.-C.-C., Chen, J.-S., Ji, J., Yeh, T.-S., Chen, L.-T., Ryu, M.-H., Kim, J.-G., Omori, T., Rha, S.-Y., Kim, T.-Y., Ryu, Okay.-W., Sakuramoto, S., Nishida, Y., Fukushima, N., Yamada, T. Sasako, M. ATTRACTION-5: A part 3 research of nivolumab plus chemotherapy as postoperative adjuvant remedy for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) most cancers. In: 2023 ASCO Annual Assembly I: gastrointestinal most cancers—gastroesophageal, pancreatic, and hepatobiliary, (abstr 4000), (2023)
Guven, D. C. et al. The affiliation between albumin ranges and survival in sufferers handled with immune checkpoint inhibitors: A scientific assessment and meta-analysis. Entrance. Mol. Biosci. 9, 1039121 (2022).
Dall’Olio, F. G. et al. Immortal time bias within the affiliation between toxicity and response for immune checkpoint inhibitors: A meta-analysis. Immunotherapy 13, 257–270 (2021).
Rizzo, A. et al. Hypertransaminasemia in most cancers sufferers receiving immunotherapy and immune-based mixtures: The MOUSEION-05 research. Most cancers Immunol. Immunother. 72, 1381–1394 (2023).
Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for domestically superior, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, part 2/3 trial. Lancet 393, 1948–1957 (2019).
Al-Batran, S. E. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in sufferers with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Outcomes from the part 2 a part of a multicentre, open-label, randomised part 2/3 trial. Lancet Oncol. 17, 1697–1708 (2016).
Kang, Y. Okay. et al. PRODIGY: A part III research of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgical procedure and adjuvant S-1 versus surgical procedure and adjuvant S-1 for resectable superior gastric most cancers. J. Clin. Oncol. 39, 2903–2913 (2021).
Giampieri, R. et al. Influence of signet-ring cell histology within the administration of sufferers with non-metastatic gastric most cancers: Outcomes from a retrospective multicenter evaluation evaluating FLOT perioperative chemotherapy vs. surgical procedure adopted by adjuvant chemotherapy. Cancers (Basel) 15, 3342 (2023).
Tsuburaya, A. et al. Sequential paclitaxel adopted by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric most cancers (SAMIT): A part 3 factorial randomised managed trial. Lancet Oncol. 15, 886–893 (2014).
Su, L. et al. POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric most cancers: Examine protocol for a randomized managed trial, FNF-014 trial. Entrance Med. (Lausanne) 9, 861777 (2022).
Shitara, Okay. et al. Nab-paclitaxel versus solvent-based paclitaxel in sufferers with beforehand handled superior gastric most cancers (ABSOLUTE): An open-label, randomised, non-inferiority, part 3 trial. Lancet Gastroenterol. Hepatol. 2, 277–287 (2017).
He, M. M. et al. Section II medical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated sufferers with metastatic gastric most cancers. Most cancers Sci. 109, 3575–3582 (2018).
Cui, Y. et al. Section I research of adjuvant chemotherapy with nab-paclitaxel and S-1 for stage III Lauren’s diffuse-type gastric most cancers after D2 resection (NORDICA research). Most cancers Med. 12, 1114–1121 (2023).
Cheng, X. et al. Adjuvant albumin-bound paclitaxel mixed with S-1 vs. oxaliplatin mixed with capecitabine after D2 gastrectomy in sufferers with stage III gastric adenocarcinoma: A part III multicenter, open-label, randomized managed medical trial protocol. BMC Most cancers 21, 56 (2021).
Cheng, X. et al. The function of oxaliplatin within the adjuvant setting of various Lauren’s kind of gastric adenocarcinoma after D2 gastrectomy: An actual-world research. Gastric Most cancers 22, 587–597 (2019).
Sasaki, Y. et al. Section II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric most cancers. Most cancers Sci. 105, 812–817 (2014).
Ma, J. et al. Evaluation of the efficacy and security of paclitaxel (albumin-bound) mixed with S-1 and oxaliplatin mixed with S-1 within the first-line remedy of superior gastric most cancers: A cohort research. J. Gastrointest. Oncol. 13, 630–636 (2022).
